| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Financial Officer
2 companies
Robert C. Goeltz II is Chief Financial Officer at RCUS and has filed Form 4s across 2 companies. Robert C. Goeltz II's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $1.7M at current prices.
Historically, Robert C. Goeltz II's trades have earned a strong insider score of 72/100 across 12 rated trades. Over a 12-month horizon, 85.7% of those trades were profitable, with an average 12-month return of +11.6%.
The biggest single holding is RCUS (~$1.6M) as Chief Financial Officer. The RCUS filings lean toward selling, a net 45,183 shares.
Robert C. Goeltz II has 29 Form 4 filings on record from January 2016 to May 2026, across 2 companies: Chief Financial Officer at Arcus Biosciences (RCUS), 2020–2026; Chief Financial Officer at CytomX Therapeutics (CTMX), 2016–2017.
The 46 reported transactions were 19 open-market sales, 9 option or other derivative awards, 7 stock awards and 7 option exercises, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 1 purchase worth about $108K and 11 sales worth about $1.6M.
The only open-market purchase was 5,000 shares of RCUS at an average $21.57 on September 9, 2020, about $108K.
The largest open-market sale was 21,517 shares of CTMX at an average $19.81 on March 20, 2017, about $426K.
All 8 sales since April 2023 were made under a Rule 10b5-1 trading plan, set up in advance.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| May 11, 2026 | RCUS Arcus Biosciences, Inc. | Chief Financial Officer | Sell10b5-1 | 7,763 | $25.63 | $198,965.69 | -8.4% | +15.5% | - | |
| Dec 31, 2025 | RCUS Arcus Biosciences, Inc. | Chief Financial Officer | Sell10b5-1 | 6,552 | $23.38 | $153,185.76 | -8.8% | -9.4% | - | |
| Dec 17, 2025 | RCUS Arcus Biosciences, Inc. | Chief Financial Officer | Sell10b5-1 | 12,662 | $22.01 | $278,739.20 | -14.5% | +1.4% | - | |
| Nov 26, 2025 | RCUS Arcus Biosciences, Inc. | Chief Financial Officer | Sell10b5-1 | 5,000 | $25.00 | $125,000.00 | -5.4% | -21.0% | - | |
| Oct 28, 2025 | RCUS Arcus Biosciences, Inc. | Chief Financial Officer | Sell10b5-1 | 5,000 | $20.00 | $100,000.00 | -5.1% | +13.1% | -6.7% | |
| Dec 31, 2024 | RCUS Arcus Biosciences, Inc. | Chief Financial Officer | Sell10b5-1 | 3,594 | $15.00 | $53,910.00 | -5.6% | -47.3% | +60.0% | |
| Jan 2, 2024 | RCUS Arcus Biosciences, Inc. | Chief Financial Officer | Sell10b5-1 | 2,004 | $20.00 | $40,080.00 | -3.7% | -6.1% | -23.1% | |
| Jun 7, 2023 | RCUS Arcus Biosciences, Inc. | Chief Financial Officer | Sell10b5-1 | 4,049 | $20.04 | $81,141.96 | -6.4% | +6.9% | -22.7% | |
| Dec 16, 2022 | RCUS Arcus Biosciences, Inc. | Chief Financial Officer | Sell | 2,453 | $30.75 | $75,429.57 | -17.5% | -45.1% | -41.3% | |
| Dec 17, 2021 | RCUS Arcus Biosciences, Inc. | Chief Financial Officer | Sell | 1,106 | $40.12 | $44,376.01 | -13.6% | -17.1% | -25.7% |